Qualia NAD+® Increases NAD+ In Human Participants: A Randomized, Double-Blind, Placebo-Controlled Study

Sarah A. Blomquist[1], Gregory Kelly[1], Sara Adães[1], Abhimanyu Ardagh[1], Shawn Ramer[1], William Scuba[1]

[1]Research and Development, Qualia Life Sciences, Carlsbad, CA, 92008, USA

Corresponding Author
William Scuba
bill@qualialife.com
5938 Priestly Dr., Suite 200
Carlsbad, CA 92008

Other author email addresses: Blomquist SA (sblomq@qualialife.com), Kelly G, (greg@qualialife.com), Adães S (sara@qualialife.com), Abhimanyu A. (Abhi@qualialife.com), Ramer S (shawn@qualialife.com)

Keywords: NAD, NADH, aging, longevity, healthspan

Abstract

Nicotinamide adenine dinucleotide (NAD) is a crucial coenzyme involved in cellular energy homeostasis whose levels decline notably with aging, which has prompted interest in NAD+ boosting to combat age-related diseases and dysfunction. Numerous clinical trials have demonstrated safety and efficacy for B3 vitamins like nicotinamide riboside (NR) to increase NAD+ levels and augment the NAD+ metabolome. Limited impact on clinically relevant outcomes or quality of life have been demonstrated, however. This randomized, double-blind, placebo-controlled study examined the effects of Qualia NAD+® on whole blood NAD+ levels and quality of life measures. Twenty-five healthy adults aged 40 - 65 (56% female) consumed Qualia NAD+ (n = 9) or placebo (n = 16) for 28 consecutive days. NAD+ levels were measured using a novel self-administered, non-invasive blood spot assay test conducted at baseline and at study end, while quality of life measures were reported bi-weekly. Overall, Qualia NAD+ significantly increased NAD+ levels an average of 74% compared to a 4% increase observed in the placebo group ($p < 0.001$). Within-groups comparisons for Qualia NAD+, and changes in NAD+ levels comparing Qualia NAD+ and placebo were also significant ($p < 0.001$). Improvements in the overall and somatic categories ($p = 0.02$ and $p = 0.04$) were observed for males only comparing baseline to day 28, while no other quality of life changes were noted. Qualia NAD+, a novel nutraceutical formulated with multiple vitamins, nutrients, and botanical compounds, effectively

increased whole blood NAD+ levels and improved some symptoms of aging in males. Clinicaltrials.gov identifier: NCT06812416.

Introduction

Since the discovery of nicotinamide adenine dinucleotide (NAD[H]) over a century ago[1] it has received the reputation as a universal energy- and signal-carrying molecule, as well as a super-centenarian molecule. Besides its essential role as a coenzyme in cellular oxidation-reduction (redox) reactions that are fundamental to almost all metabolic pathways, NAD(H) levels decline during chronological aging in both animals[2,3] and humans[4-10], and in age-related conditions like diabetes, cardiovascular and neurodegenerative diseases[11-17]. The finite pool of NAD+ is also under competition for use by NAD+-dependent enzymes including poly-ADP-ribose polymerases (PARPs), sirtuins (SIRT) and cluster of differentiation (CD38) in DNA repair, cellular signaling, immunity and inflammation, respectively. These roles of NAD+ are involved in the modulation of healthspan and lifespan[18-22]. With aging, these NAD+-dependent enzymes face increased stress, leading to a higher demand for resources like NAD+[3,4,23-25]. For these reasons, there has been tremendous interest in boosting NAD+ levels. Emerging preclinical and clinical evidence suggests this may mitigate age-related disease and dysfunction[26-30].

NAD is an organic cofactor synthesized via the *De Novo* Pathway starting from the essential amino acid L-tryptophan, via the Preiss-Handler Pathway using the B3 vitamin nicotinic acid, via the Salvage Pathway using the B3 vitamin nicotinamide riboside (NR), and via the Reduced Salvage Pathway starting with the reduced forms of NR and nicotinamide mononucleotide (NMN) (**Figure 1**). Over a dozen clinical trials have examined approaches to increase NAD+ and associated health outcomes, primarily by administering different forms of B3 vitamins that enter the Salvage pathways. For example, in a randomized controlled trial (RCT) with 133 healthy overweight adults aged 40 - 60, consumption of 100, 300 and 1000 mg Niagen® NR and dose-dependently and significantly increased whole blood NAD+ by an average of 22%, 51% and 142%, respectively, within 2 weeks; increases were sustained up to 8 weeks[31]. Studies have collectively demonstrated the safety of the NAD+ boosters NR and NMN when administered at various doses for periods of up to 26 weeks, with one trial extending for two years[12,32].

In its redox role, NAD(H)'s oxidized form, NAD+, accepts high-energy electrons to form NADH, which then donates the electrons to the electron transport chain (ETC) for adenosine triphosphate (ATP) synthesis. Shifting from NAD+ to NADH is essential for catabolic processes such as glycolysis, fatty acid oxidation, and the citric acid cycle. NAD+ can also acquire a phosphate on the adenine ribose to form NADP+. The interconversion between oxidized NADP+ and reduced NADPH drives anabolic processes like fatty acid synthesis, cholesterol, and nucleic acid production. NAD+/NADH and NADP+/NADPH ratios are central in regulating metabolism and may be more important than the amount of NAD+ in isolation, underscoring the importance of also considering the impact of the broader NAD+ metabolome in age-related disease and dysfunction[6,33,34].

Studies combining B3 vitamins with additional nutrients or ingredients have also revealed promising modulation to the broader NAD+ metabolome and clinical biomarkers. A RCT examined the consumption of nicotinamide and D-ribose (RiaGev®) in 18 healthy adults aged 35 - 65 and observed that 1520 mg taken twice daily for 7 days significantly increased NAD+ by ~10% and NADP+ by ~27% at day 5[35]. Improvements in glutathione, blood glucose, waking salivary cortisol, and quality of life measures were also noted. Another RCT administered Nuchido TIME+® (500 mg nicotinamide plus other nutrients and ingredients) in 26 healthy adults aged 21 - 72 and observed increased NAD+ concentrations in whole blood by an average of 26.5%. They also noted increases in SIRT1 and nicotinamide phosphoribosyltransferase (NAMPT) in peripheral blood mononuclear cells (PBMCs), reduced pro-inflammatory cytokines and glycated serum protein, and a shift in the glycosylation profile of immunoglobulin G toward a younger biological age[36]. Overall, B3 supplementation effectively boosts NAD+ levels and augments the NAD+ metabolome, but its impact on clinical outcomes and quality of life is still limited (studies reviewed in more detail by Freeberg et al[32]).

Qualia NAD+ was developed using a complex systems science approach with the intent to holistically support NAD+ metabolism by (i) delivering multiple B3 vitamers (NR, nicotinic acid, nicotinamide) that rely on different pathways and/or enzymes before converging on NAD+, and (ii) enhancing the activity of these NAD+-synthesizing enzymes using a combination of a magnesium, resveratrol, other B vitamins, and a coffee fruit extract standardized for caffeine (**Figure 1**). Therefore, the objective of this study was to examine the impact of Qualia NAD+ on changes in (i) NAD+ levels as measured by a self-administered, non-invasive blood-spot assay card, and (ii) quality of life measures. Although NAD+ and its metabolites exhibit stability challenges when measured in various biological tissues[6,37], NAD+ may be stabilized by a treated assay card[37-40]. To test our objective, we gave healthy adults aged 40 - 65 either Qualia NAD+ or a placebo for 28 consecutive days, then compared baseline measurements of whole blood NAD+ levels and quality of life survey scores to their respective end values.

Methods

Study product

Qualia NAD+ (Qualia Life Sciences, Carlsbad, CA, USA) is a novel dietary supplement formulated to support the maintenance and enhancement of NAD+ levels. The serving size of two dietary capsules contains the following: 0.32 mg vitamin B1, 0.4 mg vitamin B2, 254 mg of vitamin B3, (as 234 mg niacinamide [also nicotinamide] and 20 mg niacin [nicotinic acid]), 0.49 mg vitamin B6, 166 mcg dietary folate equivalents (DFE) folate, 1.5 mcg vitamin B12, 37.5 mcg biotin, 1.375 mg vitamin B5, 50 mg magnesium (as Aquamin® magnesium hydroxide from seawater [Marigot Ltd., County Cork, Ireland]), 300 mg Niagen® (nicotinamide riboside chloride from Chromadex Corp., CA, USA), 150 mg trace mineral blend (Aquamin®), 50 mg trans-resveratrol, and 28 mg caffeine from organic Coffeeberry® (Futureceuticals, USA) whole coffee fruit extract. All of these ingredients meet the criteria for dietary supplements established by the FDA, and all dosages are safe.

Study design and intervention

The current study is a randomized, double-blind, placebo-controlled parallel trial. The trial was retrospectively registered in Clinicaltrials.gov in February 2025 (identifier: NCT06812416). All participants were randomly assigned in a 1:1 ratio, stratified based on age and gender, to receive a 28 day supply of either Qualia NAD+ or placebo (Nu-Flow®, rice powder in a cellulose/vegetable capsule) to be taken daily in the morning, with or without food. The primary outcome was to investigate the efficacy of Qualia NAD+ in increasing NAD+ levels in blood samples at the end of study compared to baseline and placebo, and the secondary outcomes were findings from health-related quality of life questionnaires.

Blinding

To ensure that all subjects and researchers were unaware of the treatment assignments, a Qualia Life Sciences staff member unassociated with the research team labeled supplement bottles A or B. The research team was blinded to the content of the bottles and the information was kept confidential until study conclusion. In the event of an emergency or if the participant decided to not participate, their condition was revealed.

Participants

Participants were recruited in 2 separate cohorts via an online recruitment platform. Interested participants completed a prescreen survey to determine eligibility. Adults who met the inclusion criteria were contacted to discuss the intervention and obtain informed consent. Subjects were included if they were healthy male and female participants between the ages of 40 - 65 and were willing to: provide a valid cell phone number and receive text communications, complete questionnaires associated with the study, abstain from supplements or products containing vitamin B3 four weeks prior to baseline and through the intervention, continue taking any supplements they regularly use (with the exception of those containing vitamin B3) during the study period, and self-administer the NAD+ fingerstick test at baseline and end of study. The exclusion criteria included: women who were pregnant, breastfeeding, or planning to become pregnant during the trial, known food intolerance/allergy to any ingredients in the product, record of significant cardiovascular events in the last 6 months, currently taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines, currently on immunosuppressive therapy, those with psychiatric conditions, neurologic disorders, endocrine disorders, or cancer, or those who were incompatible with the test protocol or unable to provide consent.

Ethics

The study protocol was approved by the Advarra Institutional Review Board and adheres to international ethical standards for human research, including the principles outlined in the Declaration of Helsinki. Participants provided written informed consent before data collection. All authors were offered full access to the study data and reviewed and approved the final manuscript.

NAD+ levels testing

Revvity (previously part of PerkinElmer) developed a non-invasive, self-administered blood drop assay card to measure whole blood NAD+ that requires participants to draw drops of blood from the finger. NAD+ measurements were conducted using high-resolution liquid

chromatography/tandem mass spectrometry (LC-MS/MS) and the analyses were conducted at a CLIA-/CAP-accredited clinical genomics and biochemical laboratory.

Aging Males Symptoms Scale

The Aging Males' Symptoms (AMS) Scale is a standardized tool designed to assess symptoms of health-related quality of life and severity of symptoms in aging males over time[41]. The questionnaire consists of 17 items grouped into 3 categories: psychological, somato-vegetative, and sexual. Each item is scored on a severity scale ranging from 1 to 5, where higher scores indicate more severe symptoms. While it can be used in males of all ages, it was designed with men over 40 in mind and is used internationally for clinical research. Participants were asked to complete this survey bi-weekly (baseline, days 14 and 28).

Aging Females Symptoms Scale

The AMS scale was modified for this study to create a version that could be used with females, however most of the questions are gender-neutral and can be used for all participants. Questions 14-16 in the AMS were male-specific, therefore question 14 has been modified to produce a female version and questions 15 and 16 were eliminated. The same scoring and severity scale were applied as in the AMS. Participants were asked to complete this survey bi-weekly (baseline, days 14 and 28).

RAND-36

The 36-Item Short Form Survey (SF-36) was developed by RAND as part of the Medical Outcomes Study[42,43]. Questions are grouped into eight subscales intended to assess physical functioning, bodily pain, role limitations due to physical health problems, role limitations due to personal or emotional problems, emotional well-being, social functioning, energy/fatigue, and general health perceptions. It also includes a single item that provides an indication of perceived change in health. Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100, respectively. Scores represent the percentage of total possible scores achieved. A high score defines a more favorable health state. Participants were asked to complete this survey bi-weekly (baseline, days 14 and 28).

Safety and tolerability

Every day participants were asked to complete 9 questions in a self-reported daily diary to assess adherence and side effects. They were also asked to record how many capsules they took, the time of day they were taken, and whether the capsules were taken with food.

On a weekly basis, participants were also asked to complete a safety and tolerability survey. The possible responses for the safety and tolerability survey were: not at all, a little, a moderate amount, a lot, and a great deal, with scores corresponding from 0-4, respectively.

Statistical analysis

NAD+ data were analyzed in Python using an independent t-test to compare between groups and a dependent t-test to assess changes within groups from baseline to the end of the study (day 28). All survey data were analyzed in Python using a linear mixed-effects model to compare within-group and between-group differences over time compared to baseline. The model included

fixed effects for group (Qualia NAD+ vs. placebo), time (baseline, days 14, 28), and the interaction between group and time, as well as a random effect for participants to account for repeated measurements within individuals. The models were fitted using a maximum likelihood estimation method to optimize parameter estimates. Effect sizes and confidence intervals (same scale as the measured outcome) are reported for between-groups comparisons. Participant data was excluded from the analysis for the following reasons (i) the participant indicated taking <80% of the product dosage over the trial period and (ii) the data was recorded outside the designated window of time for that assessment. The sample size was estimated for the study design, yielding 80% power to detect an effect (Cohen's d = 0.80) with a two-tailed t-test at a 0.05 significance level.

Results



Figure 1: NAD+ Metabolism and Qualia NAD+ Supplementation Targets. Enzymes are colored orange and pathway support by Qualia NAD+ is colored blue and designated by + and the compound, nutrient, or "Supplementation", meaning the B3 vitamin itself was provided. AK: adenosine kinase; BC: Vitamin B complex; Caf: Caffeine, CD38: Cluster of differentiation 38; Mag: Magnesium; NAAD: nicotinic acid adenine dinucleotide; NADS: NAD+ synthase; NAMPT: nicotinamide phosphoribosyltransferase; NAPRT: nicotinic acid phosphoribosyltransferase; NMNATs: nicotinate N-methyltransferases; NRKs: nicotinamide riboside kinases; PARPs: poly (ADP-ribose) polymerases; QPRT: quinolinate phosphoribosyl transferase; SIRTs: sirtuins

Study population

Participants were recruited in 2 separate cohorts between September - October 2023 and during January 2024. This study was conducted between October 2023 and March 2024. Ninety-two

adults were recruited and sent at-home finger stick blood kits to measure initial blood NAD+ levels prior to beginning supplementation. Forty-nine participants successfully completed the initial test to obtain their baseline NAD+ measurements and were instructed to take Qualia NAD+ or placebo. Twenty-five of the 49 participants successfully completed a second NAD+ test after taking Qualia NAD+ or a placebo for 28 days. The participants who had both initial and final NAD+ measurements were aged 40 to 64 years old with an average age of 49.5 years. At baseline, no significant differences comparing NAD+ levels in the Qualia NAD+ and placebo groups were observed ($p = 0.73$). Participants were a mix of females ($n = 14$) and males ($n = 11$). Data analysis for NAD+ levels is based on these 25 participants who had both initial and final NAD+ measurements. The most common reasons for failing to successfully complete NAD+ measurements were: (i) failure to send in the initial or final at-home finger stick blood kits to the lab for analysis, (ii) insufficient blood sample of the submitted test kit, and (iii) too much time having elapsed between when the sample was collected and returned to the lab. Fifty-eight participants were included in the survey analysis. Reasons for excluding participants from the survey analysis are the following: (i) 15 participants did not meet the dosage threshold of 80% (described in methods), (ii) 18 participants only completed the baseline survey, and (iii) 6 participants did not complete any surveys.

Primary endpoint

Participants receiving Qualia NAD+ exhibited a mean increase in NAD+ levels of 14.56 μM (74.1%) while the placebo group experienced a mean increase of 0.71 μM (4%). Compared to baseline values, Qualia NAD+ significantly increased NAD+ ($p < 0.001$) (**Table 1**). Both the final between-group differences ($p < 0.001$, Cohen's $d = 2.88$, 95% CI [9.98, 18.88]), and the changes in NAD+ levels between groups were statistically significant at the study's conclusion ($p < 0.001$, Cohen's $d = 3.31$, 95% CI [10.2, 17.5]). Intraindividual variability in response to Qualia NAD+ supplementation was observed, with changes from baseline ranging from 29% to 134% (median 78%), as shown in **Figure 2.**

Group	n	Baseline Value (μM)	End Value (μM)	Change (μM)	P-value (within-group)
NAD+	9	19.64 ± 3.63	34.20 ± 5.88*	14.56 ± 5.79*	< 0.001
Placebo	16	19.06 ± 4.44	19.77 ± 4.70	0.71 ± 3.00	0.35

Table 1: Descriptive Statistics for Group Comparisons. Means are shown with ± standard deviations. The change value is the end value (day 28) minus the baseline value. * $p < 0.001$ when compared to the placebo group.



Figure 2: NAD+ Levels in the Qualia NAD+ and Placebo Groups. NAD values were measured using the self-administered NAD+ fingerstick at the baseline (beginning of the study) and end values were measured after 28 consecutive days of supplementation in the NAD+ group (n = 9) or the placebo group (n = 16). Solid dots connected with dotted lines represent baseline and end values for an individual participant, while the dotted line indicates changes in NAD+ values are not necessarily linear.

Secondary endpoints

Significant improvements were observed in the between-group differences for the overall ($p = 0.02$, effect size = 0.93, 95% CI [0.586, 8.651]) and somatic ($p = 0.04$, effect size = 0.76, 95% CI [0.073, 4.261]) categories for the Aging Male Symptom Scale (AMS) when comparing baseline to day 28 (p-values are not adjusted for multiple comparisons). No significant improvements were observed comparing baseline to days 14 or 28 for the Aging Female Symptom Scales (AFS) or the 36-Item Short Form Survey (RAND-36) (all $p > 0.05$, data not shown).

Safety and tolerability

No significant differences were observed between NAD+ and the placebo groups in the safety and tolerability assessment ($p > 0.05$) when comparing baseline scores to days 14 and 28, indicating Qualia NAD+ was well tolerated by participants (**Figure 3**). In the NAD+ group, only one individual dropped out of the study due to side effects.



Figure 3. Percentage of Patients Experiencing Symptoms Comparing NAD+ and Placebo Groups. Moderate symptom severity corresponds to a score of two or greater on the survey question (scores range from 0-4). Percentages were calculated by dividing the total number of participants experiencing a specific symptom by the total number of participants that filled out the survey for that time point.

Discussion

The results from this study demonstrate the novel nutraceutical, Qualia NAD+, boosts NAD+ levels an average of 74% in healthy, middle-aged males and females. Previous clinical trials reported modest increases (40 - 59%) in NAD+ using the dose of 300 mg/d nicotinamide riboside (NR) or nicotinamide mononucleotide (NMN), with larger increases requiring excess doses (1000 - 2000 mg/d)[36]. Our results suggest the blend of vitamins, nutrients and ingredients in Qualia NAD+ is more effective in supporting overall NAD+ metabolism compared to NR or NMN on their own given at similar doses. Improvements in quality of life measures were also noted only for males comparing baseline to day 28 in the overall and somatic categories, but this was not corrected for multiple comparisons. No other significant improvements in the quality of life measures were observed, possibly due to small sample size.

Individual variability in responses was also noted, where NAD+ levels increased anywhere from 29% to 134% across all participants in the Qualia NAD+ group. Similarly, interindividual variability is reported across the literature and the impact of NAD+ boosting on tissue NAD+ levels is inconsistent[32,36] Measurements of the NAD+ metabolome are also highly variable and complete

322 characterization of the metabolome lacks consistency[44]. This variability in NAD+ metabolism
323 across different populations has been attributed to multiple factors, including age, sex, and gut
324 microbiota compositions[8,28,32,36,44]. This variance highlights the complexity of NAD+
325 regulation and the necessity for a therapeutic approach that considers multiple aspects of NAD+
326 metabolism in conjunction with improved modalities for characterizing the metabolome[6,45].
327 Moreover, changes in NAD+ metabolism enzymes are known to impact NAD+ levels and lifespan,
328 offering a strong rationale for targeting them therapeutically.
329
330 Nicotinamide phosphoribosyltransferase (NAMPT), the rate-limiting step in the salvage pathway,
331 reduces with aging in animals[2,46] and humans[47-49] across various tissues, but overexpression
332 of the Nampt gene extends lifespan in mammalian cells[50,51]. Additionally, increased salvage
333 pathway activity extends lifespan in yeast[52-54]. In fact, caloric restricted-mediated NAD+
334 boosting depends on the salvage pathway rather than the *de novo* pathway[53,55,56] Nicotinate
335 N-methyltransferases (NMNATs) responsible for synthesizing NAD+ have also been shown to
336 decrease in some tissues with aging in animals[26], while Nmnat3 overexpression in mice
337 prevented age-related reductions in NAD levels[57]. Qualia NAD+ was formulated with additional
338 nutrients and ingredients besides B3 vitamins to support NAMPT and NMNATs involved in the
339 salvaging and synthesis of NAD+, respectively, as well as conversion to other molecules in the
340 NAD metabolome (NADH, NADP+, and NADPH, respectively).
341
342 Qualia NAD+ includes resveratrol to support NAMPT activity[58,59], caffeine[60-62] to support
343 nicotinamide mononucleotide adenylyltransferease (NMNAT) 2 activity (predominantly in the
344 brain and nervous system[63,64]), and a B vitamin complex to support the kynurenine pathway
345 and the energy production processes that are reliant upon the conversion of NAD+ to NADH[65-
346 67]. Magnesium (with 71 other trace minerals) was also included to support the production of
347 adenosine triphosphate (ATP), which is required to facilitate the activity of most enzymes in the
348 NAD+ biosynthesis pathway (**Figure 1**), as well as conversions between NAD+ and the other
349 NAD metabolites. Flux through the NAD+ metabolome is ultimately dependent on ATP, and ATP
350 must be bound to magnesium to be active in most cellular processes[68-70].
351
352 Besides a small number of participants, a primary limitation of our study is the fact that few other
353 human clinical trials have measured NAD+ using the novel blood-spot assay[71], though emerging
354 research suggests there is a good correlation between venous and fingerstick capillary blood
355 NAD+ measurements[8]. Future studies must validate the reproducibility of the convenient, at-
356 home NAD+ blood-spot assay. This study also did not characterize the broader NAD+
357 metabolome, which is increasingly more vital to understand the impacts of NAD+-boosting
358 therapeutics[45]. Given the current landscape of NAD+ research, it will be important to continue
359 to investigate relevant clinical and quality of life outcomes across a range of populations and with
360 a variety of NAD+ metabolome biomarkers and measurement modalities.
361
362 The research for NAD+ boosting therapeutics in mitigating age-related disease and dysfunction
363 is still in its early phases of exploration. Further, the impact of NAD+ boosting on improving healthy
364 aging and healthspan is largely unknown. In this study, Qualia NAD+ increased whole blood
365 NAD+ levels an average of 74% and this corresponded to some improvements in aging symptoms

for males, but no other improvements were observed for females, possibly due to limited sample size. To advance this field of research, subsequent studies should explore the longer-term impacts of NAD+ boosting on promoting healthspan.

Conflicts of Interest

S.A.B., W.S., G.K., and A.A. are employed by Qualia Life Sciences. S.A. and S.R. are consultants for Qualia Life Sciences**.**

Funding

This work was supported by Qualia Life Sciences. The funder provided Qualia NAD+ and was involved in the manuscript writing, editing, approval, and decision to publish.

Acknowledgments

Not applicable.

References

1. Harden, A.; Young, W.J.; Martin, C.J. The alcoholic ferment of yeast-juice. Part II.—The coferment of yeast-juice. *Proceedings of the Royal Society of London. Series B, Containing Papers of a Biological Character* **1906**, *78*, 369-375, doi:doi:10.1098/rspb.1906.0070.
2. Yoshino, J.; Mills, K.F.; Yoon, M.J.; Imai, S. Nicotinamide mononucleotide, a key NAD(+) intermediate, treats the pathophysiology of diet- and age-induced diabetes in mice. *Cell Metab* **2011**, *14*, 528-536, doi:10.1016/j.cmet.2011.08.014.
3. Camacho-Pereira, J.; Tarragó, M.G.; Chini, C.C.S.; Nin, V.; Escande, C.; Warner, G.M.; Puranik, A.S.; Schoon, R.A.; Reid, J.M.; Galina, A., et al. CD38 Dictates Age-Related NAD Decline and Mitochondrial Dysfunction through an SIRT3-Dependent Mechanism. *Cell Metab* **2016**, *23*, 1127-1139, doi:10.1016/j.cmet.2016.05.006.
4. Massudi, H.; Grant, R.; Braidy, N.; Guest, J.; Farnsworth, B.; Guillemin, G.J. Age-Associated Changes In Oxidative Stress and NAD+ Metabolism In Human Tissue. *PLOS ONE* **2012**, *7*, e42357, doi:10.1371/journal.pone.0042357.
5. Zhu, X.-H.; Lu, M.; Lee, B.-Y.; Ugurbil, K.; Chen, W. In vivo NAD assay reveals the intracellular NAD contents and redox state in healthy human brain and their age dependences. *Proceedings of the National Academy of Sciences* **2015**, *112*, 2876-2881, doi:10.1073/pnas.1417921112.
6. Clement, J.; Wong, M.; Poljak, A.; Sachdev, P.; Braidy, N. The Plasma NAD+ Metabolome Is Dysregulated in “Normal” Aging. *Rejuvenation Research* **2018**, *22*, 121-130, doi:10.1089/rej.2018.2077.
7. Pospieszna, B.; Kusy, K.; Slominska, E.M.; Zieliński, J.; Ciekot-Sołtysiak, M. Erythrocyte nicotinamide adenine dinucleotide concentration is enhanced by systematic sports participation. *BMC Sports Sci Med Rehabil* **2024**, *16*, 216, doi:10.1186/s13102-024-00999-y.

8. Wang, P.; Chen, M.; Hou, Y.; Luan, J.; Liu, R.; Chen, L.; Hu, M.; Yu, Q. Fingerstick blood assay maps real-world NAD(+) disparity across gender and age. *Aging Cell* **2023**, *22*, e13965, doi:10.1111/acel.13965.
9. Janssens, G.E.; Grevendonk, L.; Perez, R.Z.; Schomakers, B.V.; de Vogel-van den Bosch, J.; Geurts, J.M.W.; van Weeghel, M.; Schrauwen, P.; Houtkooper, R.H.; Hoeks, J. Healthy aging and muscle function are positively associated with NAD(+) abundance in humans. *Nat Aging* **2022**, *2*, 254-263, doi:10.1038/s43587-022-00174-3.
10. Guo, R.; Yang, S.; Wiesner, H.M.; Li, Y.; Zhao, Y.; Liang, Z.-P.; Chen, W.; Zhu, X.-H. Mapping intracellular NAD content in entire human brain using phosphorus-31 MR spectroscopic imaging at 7 Tesla. *Frontiers in Neuroscience* **2024**, *18*, doi:10.3389/fnins.2024.1389111.
11. Kataura, T.; Sedlackova, L.; Otten, E.G.; Kumari, R.; Shapira, D.; Scialo, F.; Stefanatos, R.; Ishikawa, K.-i.; Kelly, G.; Seranova, E., et al. Autophagy promotes cell survival by maintaining NAD levels. *Developmental Cell* **2022**, *57*, 2584-2598.e2511, doi:10.1016/j.devcel.2022.10.008.
12. Mills, K.F.; Yoshida, S.; Stein, L.R.; Grozio, A.; Kubota, S.; Sasaki, Y.; Redpath, P.; Migaud, M.E.; Apte, R.S.; Uchida, K., et al. Long-Term Administration of Nicotinamide Mononucleotide Mitigates Age-Associated Physiological Decline in Mice. *Cell Metab* **2016**, *24*, 795-806, doi:10.1016/j.cmet.2016.09.013.
13. Diguet, N.; Trammell, S.A.J.; Tannous, C.; Deloux, R.; Piquereau, J.; Mougenot, N.; Gouge, A.; Gressette, M.; Manoury, B.; Blanc, J., et al. Nicotinamide Riboside Preserves Cardiac Function in a Mouse Model of Dilated Cardiomyopathy. *Circulation* **2018**, *137*, 2256-2273, doi:10.1161/CIRCULATIONAHA.116.026099.
14. Hou, Y.; Dan, X.; Babbar, M.; Wei, Y.; Hasselbalch, S.G.; Croteau, D.L.; Bohr, V.A. Ageing as a risk factor for neurodegenerative disease. *Nature Reviews Neurology* **2019**, *15*, 565-581, doi:10.1038/s41582-019-0244-7.
15. Yulug, B.; Altay, O.; Li, X.; Hanoglu, L.; Cankaya, S.; Lam, S.; Yang, H.; Coskun, E.; İdil, E.; Nogaylar, R., et al. Combined Metabolic Activators Improve Cognitive Functions without Altering Motor Scores in Parkinson's Disease. *medRxiv* **2021**, 10.1101/2021.07.28.21261293, 2021.2007.2028.21261293, doi:10.1101/2021.07.28.21261293.
16. Yulug, B.; Altay, O.; Li, X.; Hanoglu, L.; Cankaya, S.; Lam, S.; Yang, H.; Coskun, E.; İdil, E.; Nogaylar, R., et al. Combined Metabolic Activators Improves Cognitive Functions in Alzheimer's Disease. *medRxiv* **2021**, 10.1101/2021.07.14.21260511, 2021.2007.2014.21260511, doi:10.1101/2021.07.14.21260511.
17. Verdin, E. NAD^+ in aging, metabolism, and neurodegeneration. *Science* **2015**, *350*, 1208-1213, doi:10.1126/science.aac4854.
18. Bai, P.; Cantó, C.; Oudart, H.; Brunyánszki, A.; Cen, Y.; Thomas, C.; Yamamoto, H.; Huber, A.; Kiss, B.; Houtkooper, R.H., et al. PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. *Cell Metab* **2011**, *13*, 461-468, doi:10.1016/j.cmet.2011.03.004.
19. Mottahedeh, J.; Haffner, M.C.; Grogan, T.R.; Hashimoto, T.; Crowell, P.D.; Beltran, H.; Sboner, A.; Bareja, R.; Esopi, D.; Isaacs, W.B., et al. CD38 is methylated in prostate cancer and regulates extracellular NAD(). *Cancer Metab* **2018**, *6*, 13, doi:10.1186/s40170-018-0186-3.
20. Imai, S. The NAD World: a new systemic regulatory network for metabolism and aging--Sirt1, systemic NAD biosynthesis, and their importance. *Cell Biochem Biophys* **2009**, *53*, 65-74, doi:10.1007/s12013-008-9041-4.
21. Chini, E.N. CD38 as a regulator of cellular NAD: a novel potential pharmacological target for metabolic conditions. *Curr Pharm Des* **2009**, *15*, 57-63, doi:10.2174/138161209787185788.

22. Hurtado-Bagès, S.; Knobloch, G.; Ladurner, A.G.; Buschbeck, M. The taming of PARP1 and its impact on NAD(+) metabolism. *Mol Metab* **2020**, *38*, 100950, doi:10.1016/j.molmet.2020.01.014.
23. Mouchiroud, L.; Houtkooper, R.H.; Moullan, N.; Katsyuba, E.; Ryu, D.; Cantó, C.; Mottis, A.; Jo, Y.S.; Viswanathan, M.; Schoonjans, K., et al. The NAD(+)/Sirtuin Pathway Modulates Longevity through Activation of Mitochondrial UPR and FOXO Signaling. *Cell* **2013**, *154*, 430-441, doi:10.1016/j.cell.2013.06.016.
24. Chini, E.N.; Chini, C.C.S.; Espindola Netto, J.M.; de Oliveira, G.C.; van Schooten, W. The Pharmacology of CD38/NADase: An Emerging Target in Cancer and Diseases of Aging. *Trends Pharmacol Sci* **2018**, *39*, 424-436, doi:10.1016/j.tips.2018.02.001.
25. Ubaida-Mohien, C.; Lyashkov, A.; Gonzalez-Freire, M.; Tharakan, R.; Shardell, M.; Moaddel, R.; Semba, R.D.; Chia, C.W.; Gorospe, M.; Sen, R., et al. Discovery proteomics in aging human skeletal muscle finds change in spliceosome, immunity, proteostasis and mitochondria. *Elife* **2019**, *8*, doi:10.7554/eLife.49874.
26. McReynolds, M.R.; Chellappa, K.; Baur, J.A. Age-related NAD(+) decline. *Exp Gerontol* **2020**, *134*, 110888, doi:10.1016/j.exger.2020.110888.
27. Fang, E.F.; Lautrup, S.; Hou, Y.; Demarest, T.G.; Croteau, D.L.; Mattson, M.P.; Bohr, V.A. NAD(+) in Aging: Molecular Mechanisms and Translational Implications. *Trends Mol Med* **2017**, *23*, 899-916, doi:10.1016/j.molmed.2017.08.001.
28. Iqbal, T.; Nakagawa, T. The therapeutic perspective of NAD(+) precursors in age-related diseases. *Biochem Biophys Res Commun* **2024**, *702*, 149590, doi:10.1016/j.bbrc.2024.149590.
29. Poljšak, B.; Kovač, V.; Špalj, S.; Milisav, I. The Central Role of the NAD+ Molecule in the Development of Aging and the Prevention of Chronic Age-Related Diseases: Strategies for NAD+ Modulation. *Int J Mol Sci* **2023**, *24*, doi:10.3390/ijms24032959.
30. Gilmour, B.C.; Gudmundsrud, R.; Frank, J.; Hov, A.; Lautrup, S.; Aman, Y.; Røsjø, H.; Brenner, C.; Ziegler, M.; Tysnes, O.B., et al. Targeting NAD(+) in translational research to relieve diseases and conditions of metabolic stress and ageing. *Mech Ageing Dev* **2020**, *186*, 111208, doi:10.1016/j.mad.2020.111208.
31. Conze, D.; Brenner, C.; Kruger, C.L. Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. *Scientific Reports* **2019**, *9*, 9772, doi:10.1038/s41598-019-46120-z.
32. Freeberg, K.A.; Udovich, C.C.; Martens, C.R.; Seals, D.R.; Craighead, D.H. Dietary Supplementation With NAD+-Boosting Compounds in Humans: Current Knowledge and Future Directions. *J Gerontol A Biol Sci Med Sci* **2023**, *78*, 2435-2448, doi:10.1093/gerona/glad106.
33. Ying, W. NAD+/NADH and NADP+/NADPH in Cellular Functions and Cell Death: Regulation and Biological Consequences. *Antioxidants & Redox Signaling* **2007**, *10*, 179-206, doi:10.1089/ars.2007.1672.
34. Schwarzmann, L.; Pliquett, R.U.; Simm, A.; Bartling, B. Sex-related differences in human plasma NAD+/NADH levels depend on age. *Biosci Rep* **2021**, *41*, doi:10.1042/bsr20200340.
35. Xue, Y.; Shamp, T.; Nagana Gowda, G.A.; Crabtree, M.; Bagchi, D.; Raftery, D. A Combination of Nicotinamide and D-Ribose (RiaGev) Is Safe and Effective to Increase NAD(+) Metabolome in Healthy Middle-Aged Adults: A Randomized, Triple-Blind, Placebo-Controlled, Cross-Over Pilot Clinical Trial. *Nutrients* **2022**, *14*, doi:10.3390/nu14112219.
36. Henderson, J.D.; Quigley, S.N.Z.; Chachra, S.S.; Conlon, N.; Ford, D. The use of a systems approach to increase NAD+ in human participants. *npj Aging* **2024**, *10*, 7, doi:10.1038/s41514-023-00134-0.

37. Braidy, N.; Villalva, M.D.; Grant, R. NADomics: Measuring NAD(+) and Related Metabolites Using Liquid Chromatography Mass Spectrometry. *Life (Basel)* **2021**, *11*, doi:10.3390/life11060512.
38. Smith, S.; Ellgass, M.; Park, A.; Kaib, A.; Lindberg, H.; Burns, C.; Donti, T.; Borandi, P.J.; Hegde, M. P053: Understanding the measurement of nicotinamide adenine dinucleotide (NAD+) from dried blood spots through a population study. *Genetics in Medicine Open* **2024**, *2*, doi:10.1016/j.gimo.2024.100930.
39. Matsuyama, R.; Omata, T.; Kageyama, M.; Nakajima, R.; Kanou, M.; Yamana, K. Stabilization and quantitative measurement of nicotinamide adenine dinucleotide in human whole blood using dried blood spot sampling. *Anal Bioanal Chem* **2023**, *415*, 775-785, doi:10.1007/s00216-022-04469-7.
40. Airhart, S.E.; Shireman, L.M.; Risler, L.J.; Anderson, G.D.; Nagana Gowda, G.A.; Raftery, D.; Tian, R.; Shen, D.D.; O'Brien, K.D. An open-label, non-randomized study of the pharmacokinetics of the nutritional supplement nicotinamide riboside (NR) and its effects on blood NAD+ levels in healthy volunteers. *PLoS One* **2017**, *12*, e0186459, doi:10.1371/journal.pone.0186459.
41. Heinemann, L.A. Aging Males' Symptoms scale: a standardized instrument for the practice. *J Endocrinol Invest* **2005**, *28*, 34-38.
42. Hays, R.D.; Sherbourne, C.D.; Mazel, R.M. The RAND 36-Item Health Survey 1.0. *Health Econ* **1993**, *2*, 217-227, doi:10.1002/hec.4730020305.
43. Ware, J.E., Jr.; Sherbourne, C.D. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* **1992**, *30*, 473-483.
44. Gindri, I.M.; Ferrari, G.; Pinto, L.P.S.; Bicca, J.; Dos Santos, I.K.; Dallacosta, D.; Roesler, C.R.M. Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review. *Am J Physiol Endocrinol Metab* **2024**, *326*, E417-e427, doi:10.1152/ajpendo.00242.2023.
45. Migaud, M.E.; Ziegler, M.; Baur, J.A. Regulation of and challenges in targeting NAD(+) metabolism. *Nat Rev Mol Cell Biol* **2024**, *25*, 822-840, doi:10.1038/s41580-024-00752-w.
46. Jadeja, R.N.; Powell, F.L.; Jones, M.A.; Fuller, J.; Joseph, E.; Thounaojam, M.C.; Bartoli, M.; Martin, P.M. Loss of NAMPT in aging retinal pigment epithelium reduces NAD(+) availability and promotes cellular senescence. *Aging (Albany NY)* **2018**, *10*, 1306-1323, doi:10.18632/aging.101469.
47. de Guia, R.M.; Agerholm, M.; Nielsen, T.S.; Consitt, L.A.; Søgaard, D.; Helge, J.W.; Larsen, S.; Brandauer, J.; Houmard, J.A.; Treebak, J.T. Aerobic and resistance exercise training reverses age-dependent decline in NAD(+) salvage capacity in human skeletal muscle. *Physiol Rep* **2019**, *7*, e14139, doi:10.14814/phy2.14139.
48. Yoshida, M.; Satoh, A.; Lin, J.B.; Mills, K.F.; Sasaki, Y.; Rensing, N.; Wong, M.; Apte, R.S.; Imai, S.I. Extracellular Vesicle-Contained eNAMPT Delays Aging and Extends Lifespan in Mice. *Cell Metab* **2019**, *30*, 329-342.e325, doi:10.1016/j.cmet.2019.05.015.
49. Zhou, C.C.; Yang, X.; Hua, X.; Liu, J.; Fan, M.B.; Li, G.Q.; Song, J.; Xu, T.Y.; Li, Z.Y.; Guan, Y.F., et al. Hepatic NAD(+) deficiency as a therapeutic target for non-alcoholic fatty liver disease in ageing. *Br J Pharmacol* **2016**, *173*, 2352-2368, doi:10.1111/bph.13513.
50. Borradaile, N.M.; Pickering, J.G. Nicotinamide phosphoribosyltransferase imparts human endothelial cells with extended replicative lifespan and enhanced angiogenic capacity in a high glucose environment. *Aging Cell* **2009**, *8*, 100-112, doi:10.1111/j.1474-9726.2009.00453.x.
51. van der Veer, E.; Ho, C.; O'Neil, C.; Barbosa, N.; Scott, R.; Cregan, S.P.; Pickering, J.G. Extension of human cell lifespan by nicotinamide phosphoribosyltransferase. *J Biol Chem* **2007**, *282*, 10841-10845, doi:10.1074/jbc.C700018200.

52. Anderson, R.M.; Bitterman, K.J.; Wood, J.G.; Medvedik, O.; Sinclair, D.A. Nicotinamide and PNC1 govern lifespan extension by calorie restriction in Saccharomyces cerevisiae. *Nature* **2003**, *423*, 181-185, doi:10.1038/nature01578.
53. Lin, S.J.; Defossez, P.A.; Guarente, L. Requirement of NAD and SIR2 for life-span extension by calorie restriction in Saccharomyces cerevisiae. *Science* **2000**, *289*, 2126-2128, doi:10.1126/science.289.5487.2126.
54. Anderson, R.M.; Bitterman, K.J.; Wood, J.G.; Medvedik, O.; Cohen, H.; Lin, S.S.; Manchester, J.K.; Gordon, J.I.; Sinclair, D.A. Manipulation of a Nuclear NAD+ Salvage Pathway Delays Aging without Altering Steady-state NAD+ Levels*. *Journal of Biological Chemistry* **2002**, *277*, 18881-18890, doi:https://doi.org/10.1074/jbc.M111773200.
55. Lin, S.J.; Ford, E.; Haigis, M.; Liszt, G.; Guarente, L. Calorie restriction extends yeast life span by lowering the level of NADH. *Genes Dev* **2004**, *18*, 12-16, doi:10.1101/gad.1164804.
56. Lin, S.J.; Kaeberlein, M.; Andalis, A.A.; Sturtz, L.A.; Defossez, P.A.; Culotta, V.C.; Fink, G.R.; Guarente, L. Calorie restriction extends Saccharomyces cerevisiae lifespan by increasing respiration. *Nature* **2002**, *418*, 344-348, doi:10.1038/nature00829.
57. Gulshan, M.; Yaku, K.; Okabe, K.; Mahmood, A.; Sasaki, T.; Yamamoto, M.; Hikosaka, K.; Usui, I.; Kitamura, T.; Tobe, K., et al. Overexpression of Nmnat3 efficiently increases NAD and NGD levels and ameliorates age-associated insulin resistance. *Aging Cell* **2018**, *17*, e12798, doi:10.1111/acel.12798.
58. Schuster, S.; Penke, M.; Gorski, T.; Petzold-Quinque, S.; Damm, G.; Gebhardt, R.; Kiess, W.; Garten, A. Resveratrol Differentially Regulates NAMPT and SIRT1 in Hepatocarcinoma Cells and Primary Human Hepatocytes. *PLOS ONE* **2014**, *9*, e91045, doi:10.1371/journal.pone.0091045.
59. Lan, F.; Weikel, K.A.; Cacicedo, J.M.; Ido, Y. Resveratrol-Induced AMP-Activated Protein Kinase Activation Is Cell-Type Dependent: Lessons from Basic Research for Clinical Application. *Nutrients* **2017**, *9*, doi:10.3390/nu9070751.
60. Zwilling, M.; Theiss, C.; Matschke, V. Caffeine and NAD(+) Improve Motor Neural Integrity of Dissociated Wobbler Cells In Vitro. *Antioxidants (Basel)* **2020**, *9*, doi:10.3390/antiox9060460.
61. Ryu, W.I.; Shen, M.; Lee, Y.; Healy, R.A.; Bormann, M.K.; Cohen, B.M.; Sonntag, K.C. Nicotinamide riboside and caffeine partially restore diminished NAD availability but not altered energy metabolism in Alzheimer's disease. *Aging Cell* **2022**, *21*, e13658, doi:10.1111/acel.13658.
62. Ali, Y.O.; Bradley, G.; Lu, H.-C. Screening with an NMNAT2-MSD platform identifies small molecules that modulate NMNAT2 levels in cortical neurons. *Scientific Reports* **2017**, *7*, 43846, doi:10.1038/srep43846.
63. Mayer, P.R.; Huang, N.; Dewey, C.M.; Dries, D.R.; Zhang, H.; Yu, G. Expression, localization, and biochemical characterization of nicotinamide mononucleotide adenylyltransferase 2. *J Biol Chem* **2010**, *285*, 40387-40396, doi:10.1074/jbc.M110.178913.
64. Yaku, K.; Okabe, K.; Nakagawa, T. NAD metabolism: Implications in aging and longevity. *Ageing Res Rev* **2018**, *47*, 1-17, doi:10.1016/j.arr.2018.05.006.
65. Hanna, M.; Jaqua, E.; Nguyen, V.; Clay, J. B Vitamins: Functions and Uses in Medicine. *Perm J* **2022**, *26*, 89-97, doi:10.7812/tpp/21.204.
66. Hrubša, M.; Siatka, T.; Nejmanová, I.; Vopršalová, M.; Kujovská Krčmová, L.; Matoušová, K.; Javorská, L.; Macáková, K.; Mercolini, L.; Remião, F., et al. Biological Properties of Vitamins of the B-Complex, Part 1: Vitamins B(1), B(2), B(3), and B(5). *Nutrients* **2022**, *14*, doi:10.3390/nu14030484.

612 67. Majewski, M.; Kozlowska, A.; Thoene, M.; Lepiarczyk, E.; Grzegorzewski, W.J. Overview
613 of the role of vitamins and minerals on the kynurenine pathway in health and disease. *J*
614 *Physiol Pharmacol* **2016**, *67*, 3-19.
615 68. Lau, C.; Niere, M.; Ziegler, M. The NMN/NaMN adenylyltransferase (NMNAT) protein
616 family. *Front Biosci (Landmark Ed)* **2009**, *14*, 410-431, doi:10.2741/3252.
617 69. She, J.; Sheng, R.; Qin, Z.H. Pharmacology and Potential Implications of Nicotinamide
618 Adenine Dinucleotide Precursors. *Aging Dis* **2021**, *12*, 1879-1897,
619 doi:10.14336/ad.2021.0523.
620 70. Storer, A.C.; Cornish-Bowden, A. Concentration of MgATP2- and other ions in solution.
621 Calculation of the true concentrations of species present in mixtures of associating ions.
622 *Biochem J* **1976**, *159*, 1-5, doi:10.1042/bj1590001.
623 71. Hawkins, J.; Idoine, R.; Kwon, J.; Shao, A.; Dunne, E.; Hawkins, E.; Dawson, K.; Nkrumah-
624 Elie, Y. Randomized, placebo-controlled, pilot clinical study evaluating acute Niagen®+ IV
625 and NAD+ IV in healthy adults. *medRxiv* **2024**, 10.1101/2024.06.06.24308565,
626 2024.2006.2006.24308565, doi:10.1101/2024.06.06.24308565.
627